| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Salinomycin is a polyether ionophore antibiotic that is produced by the bacterium Streptomyces albus. It was first isolated in 1979 and has been found to have a range of biological activities, including antibacterial, antifungal, and anticancer properties. It has been shown to induce apoptosis (programmed cell death) in a range of cancer cell lines, including breast, lung, and colon cancer cells. Salinomycin has also been found to inhibit the growth of cancer stem cells. Salinomycin, a widely used antibiotic in poultry farming Actions: -Strong activity against cancer stem cells -Disrupts mitochondrial ion gradients → ROS -Non-thiol, non-NRF2 dominant Key pathways -Mitochondrial K⁺ dysregulation -ROS-mediated apoptosis -Wnt/β-catenin inhibition Chemo relevance -Generally compatible or synergistic -Not a redox buffer
|
| Source: HalifaxProj(inhibit) |
| Type: |
| Akt1 is involved in cellular survival pathways, by inhibiting apoptotic processes; Akt2 is an important signaling molecule in the insulin signaling pathway. It is required to induce glucose transport. Inhibitors: -Curcumin: downregulate AKT phosphorylation and signaling. -Resveratrol -Quercetin: inhibit the PI3K/AKT pathway. -Epigallocatechin Gallate (EGCG) -Luteolin and Apigenin: inhibit AKT phosphorylation |
| - | in-vivo, | CRC, | Caco-2 | - | vitro+vivo, | CRC, | CX-1 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:203 Target#:4 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid